Lupin officially created a new, wholly-owned subsidiary—LupinLife Consumer Healthcare Ltd—to house its consumer healthcare business. The move aligns Lupin with a growing trend among drugmakers, both Indian and global, to carve out their consumer health operations to better target the rapidly expanding self-care market in India.
Companies such as Cipla, Glenmark, Mankind Pharma, and Sanofi have already adopted similar strategies, recognizing the need for separate business models to cater to prescription drugs and over-the-counter (OTC) healthcare products.
Leadership and Strategic Direction
Anil Kaushal will lead the new subsidiary as Chief Executive Officer, bringing strategic focus and agility to Lupin’s consumer health portfolio. According to the company, this restructuring allows for more targeted investments and a dedicated approach to building strong consumer brands in the OTC space.
Positioning for Growth in the OTC Segment
Earlier this year, Lupin had announced plans to transfer its OTC business to a separate entity, valuing the transfer at approximately ₹550–650 crore. The company emphasized that the separation would help Lupin sharpen its focus on prescription drugs while allowing the OTC arm to thrive independently in a fast-growing and competitive consumer healthcare market. For FY24, Lupin’s OTC consumer healthcare business contributed ₹148 crore, roughly 1% of the company’s total standalone revenue of ₹14,666 crore.
Established Brand Portfolio Under LupinLife
LupinLife Consumer Healthcare has built a strong portfolio of scientifically formulated brands, including Softovac, Beplex Forte, Corcium, and Aptivate. These products are positioned to leverage the rising demand for preventive healthcare and wellness in India.
Why the Pharma Sector Is Spinning Off Consumer Health Units
Krishnanath Munde, Associate Director at India Ratings and Research Pvt Ltd, noted that many pharma companies, originally focused solely on prescription medications, have over time developed strong OTC and consumer brands. By spinning off these divisions, companies can streamline operations and adopt more FMCG-style promotion strategies tailored for consumer health products—while maintaining focus on their traditional pharma businesses.
Looking Ahead
With the formation of LupinLife Consumer Healthcare Ltd, Lupin joins a broader industry shift that seeks to unlock value and accelerate growth in two distinct but complementary healthcare markets—prescription pharmaceuticals and consumer wellness products. As reported by thhindubusinessline.com, the company’s move reflects its long-term vision of adapting to evolving healthcare needs and market dynamics in India.
